- NZ has obtained 60K courses of Pfizer’s antiviral drug to help people with minor symptoms from becoming very ill.
- Fisher and Paykel plans to invest in more land and buildings in the next 5 years.
- Arvida Group delivered an underlying profit of $26.6 million in H1FY22, up 30% on pcp.
NZ’s Health Minister Andrew Little announced on Monday that NZ had procured supplies of another medicine to deal with COVID-19.
NZ’s drug funding agency Pharmac has obtained 60K courses of an antiviral medicine that can be taken as a tablet and help people with minor symptoms from becoming very sick. The drug works by blocking the split of certain proteins essential to produce a fully active virus.
Pfizer’s anti-viral drug is likely to be delivered to NZ in April once it gets MedSafe’s consent.
On this note, let’s skim through how these 5 NZX healthcare stocks are faring as the year ends.
Image source: © 2021 Kalkine Media, Data source- Refinitiv
Fisher and Paykel reported a decline of 2% and 1% in its NPAT and operating revenue in H1 of FY22. However, it reported growth in new applications consumables and Homecare operating revenue.
The Group plans to invest in 3 more manufacturing facilities outside NZ over the next 5 years.
FPH ended the day 1.02% in red to close at $31.95.
Ebos Group Limited (NZX:EBO)
Ebos delivered record FY21 results with increased net profit (+15.5%) and increased dividend payments (+14.2%) to shareholders.
Ebos’ key focus areas will be environmental stewardship, packaging waste, responsible supply chain and quality management.
EBO ended the day 0.28% in green to close at $35.46.
Arvida Group Limited (NZX:ARV)
Arvida's underlying profit for the first half of FY22 was $26.6 million, up 30% over the same period last year. High staff expenses, according to the Group, would be a burden for the industry in the second half of FY22.
Arvida has issued an interim dividend of 2.5cps, which will be paid on 15 December.
ARV ended the day 1.02% in red to close at $1.94.
Pacific Edge Limited (NZX:PEB)
Pacific Edge announced a 66% increase in sales to $66.7 million for the six months ending 30 September 2021 on pcp. During that time, the Group's US sales staff grew from 16 to 28 people.
With scaled-up activities in the United States and a healthy balance sheet, PEB is well positioned to capitalise on commercial opportunities.
PEB ended the day flat to close at $1.25.
Summerset announced the auction of occupancy rights for the third quarter of 2021. One hundred ninety-nine transactions were completed throughout the quarter, with 117 new purchases and 82 resales, according to the company.
To date, sales have accounted for 95% of full-year sales in 2020.
SUM ended the day 1.24% in green to close at $13.06.
Eligible Kiwis have achieved a near-85% vaccination rate. Subsequently, the country is now better prepared to tackle new variants of COVID-19.
(NOTE: Currency is reported in NZ Dollar unless stated otherwise)